Home » Stocks » Nabriva Therapeutics

Nabriva Therapeutics PLC (NBRV)

Stock Price: $0.570 USD -0.016 (-2.75%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $0.590 +0.020 (3.49%) Oct 21, 7:20 PM

Stock Price Chart

Key Info

Market Cap 82.05M
Revenue (ttm) 8.53M
Net Income (ttm) -79.54M
Shares Out 143.96M
EPS (ttm) -0.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $0.570
Previous Close $0.586
Change ($) -0.016
Change (%) -2.75%
Day's Open 0.572
Day's Range 0.561 - 0.585
Day's Volume 1,560,363
52-Week Range 0.485 - 2.230

More Stats

Market Cap 82.05M
Enterprise Value 39.47M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 143.96M
Float n/a
EPS (basic) -0.09
EPS (diluted) -0.88
FCF / Share -0.07
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 7.04M
Short Ratio 4.45
Short % of Float n/a
Beta 2.23
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 9.62
PB Ratio 1.91
Revenue 8.53M
Operating Income -73.91M
Net Income -79.54M
Free Cash Flow -75.61M
Net Cash 42.59M
Net Cash / Share 0.30
Gross Margin -199.37%
Operating Margin -866.57%
Profit Margin -932.60%
FCF Margin -886.45%
ROA -62.13%
ROE -181.05%
ROIC -396.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 1
Overweight 0
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$1.75*
(207.02% upside)
Low
1.50
Current: $0.570
High
2.00
Target: 1.75
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue9.489.665.326.483.772.40
Revenue Growth-1.81%81.54%-17.94%72.07%57.09%-
Gross Profit9.419.665.326.483.772.40
Operating Income-79.49-114-73.77-55.05-27.76-10.70
Net Income-82.76-115-74.36-54.89-46.96-14.22
Shares Outstanding74.2050.8029.8321.4810.580.32
Earnings Per Share-0.11-0.23-0.25-0.26-0.48-4.44
Operating Cash Flow-71.89-72.72-69.35-48.33-21.86-11.41
Capital Expenditures-0.06-0.23-1.17-0.60-0.22-0.09
Free Cash Flow-71.95-72.95-70.52-48.93-22.07-11.49
Cash & Equivalents86.5910286.8883.88111-
Total Debt34.5023.720.23---
Net Cash / Debt52.0878.5186.6583.88111-
Assets94.1111095.7693.24118-
Liabilities52.8441.7913.7015.989.01-
Book Value41.2768.6382.0777.26109-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Nabriva Therapeutics PLC
Country Ireland
Employees 162
CEO Theodore R. Schroeder

Stock Information

Ticker Symbol NBRV
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NBRV
IPO Date September 18, 2015

Description

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; for the treatment of acute bacterial skin and skin structure infection; and that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, osteomyelitis, and prosthetic joint infections. It is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.